公开(公告)号：US20230365674A1

公开(公告)日：2023-11-16

申请号：US18193581

申请日：2023-03-30

Applicant: NOVARTIS AG

Inventor： John Louis DIENER ,  Lars GADTKE ,  Felix HARTLEPP ,  Tiancen HU ,  Kathrin LADETZKI-BAEHS ,  Michael John ROMANOWSKI ,  Cesare RUSSO ,  Xenia WEZLER ,  Xiaoling XIE

IPC: C07K16/28 ,  A61P9/00 ,  A61K39/395 ,  A61P13/12

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61P9/00 ,  A61P13/12 ,  C07K16/2869 ,  A61K45/06

Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.

公开(公告)号：US20240293508A1

公开(公告)日：2024-09-05

申请号：US18609420

申请日：2024-03-19

Applicant: Novartis AG

Inventor： John Louis DIENER ,  Jiaping GAO ,  Rick Jerome SCHIEBINGER

IPC: A61K38/18 ,  C07K14/50

CPC classification number: A61K38/1825 ,  C07K14/50 ,  C07K2319/30

Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.

公开(公告)号：US20240052042A1

公开(公告)日：2024-02-15

申请号：US18267403

申请日：2021-12-13

Applicant: NOVARTIS AG

Inventor： Yuichiro ADACHI ,  Jennifer R. ALLPORT-ANDERSON ,  Shaun R. COUGHLIN ,  John Louis DIENER ,  Lars GADTKE ,  Felix HARTLEPP ,  Tiancen HU ,  Alexander Wolfgang KOCH ,  Kathrin LADETZKI-BAEHS ,  Michael John ROMANOWSKI ,  Cesare RUSSO ,  Xenia Karola WEZLER ,  Xiaoling XIE

IPC: C07K16/28 ,  A61K45/06 ,  A61P9/12

CPC classification number: C07K16/2863 ,  A61K45/06 ,  A61P9/12

Abstract: The present disclosure relates to use of reversal agents which specifically bind to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies or antigen binding fragments thereof, and reverse one or more effects of the anti-NPR1 antibody or antigen binding fragments thereof (e.g., hypotensive effects).

公开(公告)号：US20230183286A1

公开(公告)日：2023-06-15

申请号：US17820005

申请日：2022-08-16

Applicant: NOVARTIS AG

Inventor： David BARNES-SEEMAN ,  Scott Louis COHEN ,  John Louis DIENER ,  Christian GAMPE ,  James ROACHE ,  Amy White ,  Sarah Louise Williams ,  Jun Yuan ,  Frederic Zecri

IPC: C07H21/02 ,  C07F9/6561 ,  C07H19/167 ,  C07H19/207 ,  C07K14/575

CPC classification number: C07H21/02 ,  C07F9/65616 ,  C07H19/167 ,  C07H19/207 ,  C07K14/5759

Abstract: The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

公开(公告)号：US20220356242A1

公开(公告)日：2022-11-10

申请号：US17348949

申请日：2021-06-16

Applicant: NOVARTIS AG

Inventor： John Louis DIENER ,  Lars GADTKE ,  Felix HARTLEPP ,  Tiancen HU ,  Kathrin LADETZKI-BAEHS ,  Michael John ROMANOWSKI ,  Cesare RUSSO ,  Xenia WEZLER ,  Xiaoling XIE

IPC: C07K16/28 ,  A61P9/00 ,  A61K39/395 ,  A61P13/12

Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.

公开(公告)号：US20180002368A1

公开(公告)日：2018-01-04

申请号：US15536516

申请日：2015-12-16

Applicant: NOVARTIS AG

Inventor： David BARNES-SEEMAN ,  Scott Louis COHEN ,  John Louis DIENER ,  Christian GAMPE ,  James ROACHE ,  Amy WHITE ,  Sarah WILLIAMS ,  Jun YUAN ,  Frederic ZECRI

IPC: C07H21/02 ,  C07F9/6561 ,  C07H19/207 ,  C07K14/575

Abstract: The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.